Developer docs
API playgroundTry for free, no card

Search company profiles

BNC KOREA

Full company profile

uuid000bk2d

Namestring
BNC KOREA
Legal namestring
주식회사 한국비엔씨 (BNC KOREA, Inc.)
Websiteurl
bnckorea.co.kr
Company typeenum
Public
Founded yearint
2007
Descriptiontext

BNC KOREA (한국비엔씨, Inc.) is a Korean bio-venture founded in August 2007 and listed on KOSDAQ since 2019 (previously KONEX from 2015). The company develops, manufactures, and commercializes medical devices, pharmaceuticals, and cosmeceuticals based on biomaterials processing technologies—principally hyaluronic acid (HA) and collagen. Its product portfolio spans HA-based dermal fillers (Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Juvegel HA+PN composite), skin boosters (Cutegel Hydro, S-DNA, H-DNA, AQUABIEN HYDRO PURE, CELLABIEN I GLOWY), the botulinum toxin type A pharmaceutical BIENOX, the HA-based anti-adhesion barrier gel Hibarry for spinal surgery, collagen-based wound dressings and tissue supplements (GentaQ, Collapleo, Collapleo Plus), and the I.st premium cosmeceutical skincare brand.

The company operates a vertically integrated manufacturing footprint including R&D laboratories with clean room and prefilled syringe equipment at its Daegu headquarters, a sales/marketing office in Seongnam (Gyeonggi-do), and a newly completed specialty pharmaceutical GMP factory in Sejong (~16,528 sqm) supporting BIENOX and drug substance production. BNC holds domestic Korean patents on HA derivative particle manufacturing and on collagen wound dressings containing drugs/antibiotics, alongside CE, ISO 13485, ISO 9001, ISO 14001, ISO 22716, GMP, and KFDA/KMFDS certifications across product lines.

BNC KOREA generates revenue through four streams: (1) medical device sales via direct domestic B2B and international export; (2) OEM/ODM manufacturing for international partners under multi-year supply contracts, anchored by a US-based customer at minimum US$3M annually and a Chinese partner at 1 million units annually; (3) pharmaceutical product sales focused on BIENOX for aesthetic and therapeutic use; and (4) I.st cosmeceutical sales through its own e-commerce platform (istcosmetics.com). The company exports to approximately 45 countries across Europe, China, Latin America, the Middle East, India, and Southeast Asia, with export revenue rising from US$1M (2016) to US$5M (2018) Export Tower milestones. As of 2020, BNC employed 111 staff including 21 research personnel, with registered capital of approximately KRW 4.6 billion.

Short descriptiontext

BNC KOREA is a Korean KOSDAQ-listed bio-venture that develops, manufactures, and exports hyaluronic acid and collagen-based medical devices, the BIENOX botulinum toxin pharmaceutical, and the I.st cosmeceutical brand to hospitals, clinics, OEM partners, and consumers across 45 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyaluronic acid fillers, biomaterial medical devices, aesthetic pharmaceuticals, collagen wound dressings, botulinum toxin products
NAICS code2 codes
  • Dental Equipment and Supplies Manufacturing339114
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Aesthetic Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Device Sales
TypeOne Time License
Description

Sales of proprietary medical devices including HA fillers (Cutegel, FLORE), anti-adhesion barriers (Hibarry), collagen wound dressings (GentaQ), and tissue supplements (Collapleo). Both domestic Korean market and international export sales through direct export and OEM partnerships.

bnckorea.co.kr
2OEM/ODM Export Manufacturing
TypeLicensing Royalties
Description

Original equipment manufacturing agreements with international companies. Includes minimum annual supply contracts for dermal fillers (US$3 million+ annually to US company) and annual supply of 1 million units to Chinese partner.

bnckorea.co.kr
3Pharmaceutical Product Sales
TypeOne Time License
Description

Sales of specialty pharmaceuticals including BIENOX (botulinum toxin type A) for export markets and domestic Korean market. Professional pharmaceutical products requiring medical prescriptions.

bnckorea.co.kr
4Cosmeceutical Products (I.st Brand)
TypeOne Time License
Description

Premium cosmetic line branded as I.st sold through company's online mall (istcosmetics.com). Includes skincare products across Premium, Special, Beauty Face, and Home Care lines.

bnckorea.co.kr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1I.st
Description

Premium cosmetic brand by BNC KOREA offering skincare products including Premium Care Line, Special Care Line, Beauty Face Line, and Home Care Line.

bnckorea.co.kr
+6 more records
Core offering1 text field

BNC KOREA is a Korean bio-venture company that develops, manufactures, and sells biomaterial-based medical devices, specialty pharmaceuticals, and cosmeceuticals. Core products include hyaluronic acid dermal fillers (Cutegel, FLORE, Juvegel), botulinum toxin type A (BIENOX), anti-adhesion barrier gel (Hibarry), collagen-based wound dressings (GentaQ) and tissue supplements (Collapleo), and the I.st premium cosmetic brand. The company operates GMP-certified manufacturing facilities and exports to 45 countries via OEM partnerships and local distributors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Clinical safety and efficacy confirmed through comparative trials at major Korean university hospitals (Gacheon University Gil Medical Center, Gangnam Severance Hospital, Korea University Ansan Hospital, St. Vincent Hospital)
+1 more record
Product overview1 text field

BNC KOREA is a Korean bio-venture company specializing in medical devices, pharmaceuticals, and cosmeceuticals. The product portfolio centers on hyaluronic acid-based dermal fillers (Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Juvegel), skin boosters (Cutegel Hydro, S-DNA, H-DNA, AQUABIEN HYDRO PURE, CELLABIEN I GLOWY), botulinum toxin (BIENOX), anti-adhesion barriers (Hibarry), collagen wound dressings and tissue supplements (GentaQ, Collapleo, Collapleo Plus), and the premium cosmeceutical brand I.st. The company operates with GMP-certified manufacturing facilities and exports to 45+ countries.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

OEM export partnership for dermal filler supply. Contract for minimum US$3 million annually, with 5-year supply agreement valued at approximately KRW 155 billion (US$73 million for initial period). BNC manufactures dermal fillers for US company under their brand.

2China Company B
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-01-01
Description

Annual supply contract for 1 million units of dermal fillers to Chinese market. CFDA certification expected 2021 for market entry. Represents significant volume commitment for China market expansion.

bnckorea.co.kr
3Local Partners in Emerging Markets
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnerships with local distributors in Brazil, Middle East, India, and Indonesia for medical device registration and market development. Partners handle regulatory registration and local distribution of dermal fillers and anti-adhesion products.

bnckorea.co.kr
4European Distribution Partners (Serbia, Bosnia, Poland)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

CE-certified dermal filler exports through distribution partners in Serbia, Bosnia, and Poland covering European market entry.

bnckorea.co.kr
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research collaboration for developing treatment technology for jaw and facial bone regeneration using tissue-forming polypeptides.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research collaboration for developing treatment materials for retinal degenerative diseases using gold nanoparticle-labeled neovascular targeting nanocomplexes.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean botulinum toxin (Botulax) and HA filler manufacturer. Closest direct competitor to BNC Korea in the domestic Korean aesthetic medicine market, with overlapping product categories (botulinum toxin, HA fillers) and global export ambitions.

TypeDirect peer
Description

Korean biopharmaceutical company developing botulinum toxin (Meditoxin/NeuBo) and HA-based dermal fillers. Direct competitor in both Korean domestic and international OEM markets for aesthetic injectables.

3LG Chem (Life Sciences Division)
TypeBroad incumbent
Description

Large Korean conglomerate with a life sciences division producing HA fillers (Yvoire) and other aesthetic/biomedical products. Much broader portfolio and greater resources than BNC Korea, but overlaps in core HA filler category.

TypeBroad incumbent
Description

Major Korean pharmaceutical company with botulinum toxin (Nabota) and aesthetic medicine presence. Competes with BNC in Korea and selected export markets with established global distribution capabilities.

TypeDirect peer
Description

UK-based aesthetic medicine company with HA filler (MaiLi) and collagen-stimulator portfolio. Comparable in scale and product focus to BNC Korea; similar OEM and global distribution model for aesthetic injectables.

6Croma-Pharma
TypeDirect peer
Description

Austrian aesthetic medicine company specializing in HA fillers, PRP, and botulinum toxin distribution. Comparable mid-sized European peer with similar product mix targeting global aesthetic medicine markets.

TypeDirect peer
Description

Swiss HA dermal filler manufacturer with global distribution. Similar specialization in premium HA-based aesthetic products and similar international export model via local distributors.

8Revance Therapeutics
TypeDirect peer
Description

US aesthetics company developing botulinum toxin (Daxxify) and HA fillers. Comparable in scale and product focus, with similar OEM/licensing opportunities in select geographies.

TypeBroad incumbent
Description

Global leader in dermatology and aesthetic medicine with Restylane, Sculptra, and Dysport franchises. Sets competitive benchmarks for HA fillers and botulinum toxin; broad incumbent rather than direct peer due to scale.

10BioPlus (Collagen Wound Care)
TypeRegional player
Description

Korean biomaterials company producing absorbable collagen-based wound dressings and surgical implants. Direct peer in collagen wound dressing and tissue supplement categories overlapping with GentaQ and Collapleo product lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BNC KOREA

Aesthetic Medical Devicesbnckorea.co.kr

BNC KOREA is a Korean KOSDAQ-listed bio-venture that develops, manufactures, and exports hyaluronic acid and collagen-based medical devices, the BIENOX botulinum toxin pharmaceutical, and the I.st cosmeceutical brand to hospitals, clinics, OEM partners, and consumers across 45 countries.

What BNC KOREA does

BNC KOREA (한국비엔씨, Inc.) is a Korean bio-venture founded in August 2007 and listed on KOSDAQ since 2019 (previously KONEX from 2015). The company develops, manufactures, and commercializes medical devices, pharmaceuticals, and cosmeceuticals based on biomaterials processing technologies—principally hyaluronic acid (HA) and collagen. Its product portfolio spans HA-based dermal fillers (Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Juvegel HA+PN composite), skin boosters (Cutegel Hydro, S-DNA, H-DNA, AQUABIEN HYDRO PURE, CELLABIEN I GLOWY), the botulinum toxin type A pharmaceutical BIENOX, the HA-based anti-adhesion barrier gel Hibarry for spinal surgery, collagen-based wound dressings and tissue supplements (GentaQ, Collapleo, Collapleo Plus), and the I.st premium cosmeceutical skincare brand.

The company operates a vertically integrated manufacturing footprint including R&D laboratories with clean room and prefilled syringe equipment at its Daegu headquarters, a sales/marketing office in Seongnam (Gyeonggi-do), and a newly completed specialty pharmaceutical GMP factory in Sejong (~16,528 sqm) supporting BIENOX and drug substance production. BNC holds domestic Korean patents on HA derivative particle manufacturing and on collagen wound dressings containing drugs/antibiotics, alongside CE, ISO 13485, ISO 9001, ISO 14001, ISO 22716, GMP, and KFDA/KMFDS certifications across product lines.

BNC KOREA generates revenue through four streams: (1) medical device sales via direct domestic B2B and international export; (2) OEM/ODM manufacturing for international partners under multi-year supply contracts, anchored by a US-based customer at minimum US$3M annually and a Chinese partner at 1 million units annually; (3) pharmaceutical product sales focused on BIENOX for aesthetic and therapeutic use; and (4) I.st cosmeceutical sales through its own e-commerce platform (istcosmetics.com). The company exports to approximately 45 countries across Europe, China, Latin America, the Middle East, India, and Southeast Asia, with export revenue rising from US$1M (2016) to US$5M (2018) Export Tower milestones. As of 2020, BNC employed 111 staff including 21 research personnel, with registered capital of approximately KRW 4.6 billion.

BNC KOREA firmographics

Firmographics
Name
BNC KOREA
Legal name
주식회사 한국비엔씨 (BNC KOREA, Inc.)
Website
https://bnckorea.co.kr
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
BNC KOREA is a Korean KOSDAQ-listed bio-venture that develops, manufactures, and exports hyaluronic acid and collagen-based medical devices, the BIENOX botulinum toxin pharmaceutical, and the I.st cosmeceutical brand to hospitals, clinics, OEM partners, and consumers across 45 countries.
Ownership category
akta.pro rank

Where BNC KOREA is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

BNC KOREA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sales of proprietary medical devices including HA fillers (Cutegel, FLORE), anti-adhesion barriers (Hibarry), collagen wound dressings (GentaQ), and tissue supplements (Collapleo). Both domestic Korean market and international export sales through direct export and OEM partnerships.
  2. OEM/ODM Export Manufacturing: Original equipment manufacturing agreements with international companies. Includes minimum annual supply contracts for dermal fillers (US$3 million+ annually to US company) and annual supply of 1 million units to Chinese partner.
  3. Pharmaceutical Product Sales: Sales of specialty pharmaceuticals including BIENOX (botulinum toxin type A) for export markets and domestic Korean market. Professional pharmaceutical products requiring medical prescriptions.
  4. Cosmeceutical Products (I.st Brand): Premium cosmetic line branded as I.st sold through company's online mall (istcosmetics.com). Includes skincare products across Premium, Special, Beauty Face, and Home Care lines.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

BNC KOREA product offering

Product offering

Core offering

BNC KOREA is a Korean bio-venture company that develops, manufactures, and sells biomaterial-based medical devices, specialty pharmaceuticals, and cosmeceuticals. Core products include hyaluronic acid dermal fillers (Cutegel, FLORE, Juvegel), botulinum toxin type A (BIENOX), anti-adhesion barrier gel (Hibarry), collagen-based wound dressings (GentaQ) and tissue supplements (Collapleo), and the I.st premium cosmetic brand. The company operates GMP-certified manufacturing facilities and exports to 45 countries via OEM partnerships and local distributors.

Product overview

BNC KOREA is a Korean bio-venture company specializing in medical devices, pharmaceuticals, and cosmeceuticals. The product portfolio centers on hyaluronic acid-based dermal fillers (Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Juvegel), skin boosters (Cutegel Hydro, S-DNA, H-DNA, AQUABIEN HYDRO PURE, CELLABIEN I GLOWY), botulinum toxin (BIENOX), anti-adhesion barriers (Hibarry), collagen wound dressings and tissue supplements (GentaQ, Collapleo, Collapleo Plus), and the premium cosmeceutical brand I.st. The company operates with GMP-certified manufacturing facilities and exports to 45+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • I.st: Premium cosmetic brand by BNC KOREA offering skincare products including Premium Care Line, Special Care Line, Beauty Face Line, and Home Care Line.
  • BIENOX
  • Cutegel/FLORE
  • Hibarry
  • GentaQ
  • Collapleo
  • Juvegel

Quantifiable outcome

  • Clinical safety and efficacy confirmed through comparative trials at major Korean university hospitals (Gacheon University Gil Medical Center, Gangnam Severance Hospital, Korea University Ansan Hospital, St. Vincent Hospital)
  • +1 more outcomes

Companies that use BNC KOREA

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

BNC KOREA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BNC KOREA partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • US-based Company AcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2017OEM export partnership for dermal filler supply. Contract for minimum US$3 million annually, with 5-year supply agreement valued at approximately KRW 155 billion (US$73 million for initial period). BNC manufactures dermal fillers for US company under their brand.
  • China Company BcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2015Annual supply contract for 1 million units of dermal fillers to Chinese market. CFDA certification expected 2021 for market entry. Represents significant volume commitment for China market expansion.
  • Local Partners in Emerging MarketsminorChannel Partner/ Reseller/ DistributorPartnerships with local distributors in Brazil, Middle East, India, and Indonesia for medical device registration and market development. Partners handle regulatory registration and local distribution of dermal fillers and anti-adhesion products.
  • European Distribution Partners (Serbia, Bosnia, Poland)minorChannel Partner/ Reseller/ DistributorCE-certified dermal filler exports through distribution partners in Serbia, Bosnia, and Poland covering European market entry.
  • Yonsei University College of DentistryminorStrategic or Co-development PartnerJoint research collaboration for developing treatment technology for jaw and facial bone regeneration using tissue-forming polypeptides.
  • Daegu Catholic University School of MedicineminorStrategic or Co-development PartnerJoint research collaboration for developing treatment materials for retinal degenerative diseases using gold nanoparticle-labeled neovascular targeting nanocomplexes.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

BNC KOREA competitors and assessment

Company assessment

Direct peers

  • Hugel: Korean botulinum toxin (Botulax) and HA filler manufacturer. Closest direct competitor to BNC Korea in the domestic Korean aesthetic medicine market, with overlapping product categories (botulinum toxin, HA fillers) and global export ambitions.
  • Medytox: Korean biopharmaceutical company developing botulinum toxin (Meditoxin/NeuBo) and HA-based dermal fillers. Direct competitor in both Korean domestic and international OEM markets for aesthetic injectables.
  • Sinclair Pharma: UK-based aesthetic medicine company with HA filler (MaiLi) and collagen-stimulator portfolio. Comparable in scale and product focus to BNC Korea; similar OEM and global distribution model for aesthetic injectables.
  • Croma-Pharma: Austrian aesthetic medicine company specializing in HA fillers, PRP, and botulinum toxin distribution. Comparable mid-sized European peer with similar product mix targeting global aesthetic medicine markets.
  • Teoxane: Swiss HA dermal filler manufacturer with global distribution. Similar specialization in premium HA-based aesthetic products and similar international export model via local distributors.
  • Revance Therapeutics: US aesthetics company developing botulinum toxin (Daxxify) and HA fillers. Comparable in scale and product focus, with similar OEM/licensing opportunities in select geographies.

Broad incumbents

  • LG Chem (Life Sciences Division): Large Korean conglomerate with a life sciences division producing HA fillers (Yvoire) and other aesthetic/biomedical products. Much broader portfolio and greater resources than BNC Korea, but overlaps in core HA filler category.
  • Daewoong Pharmaceutical: Major Korean pharmaceutical company with botulinum toxin (Nabota) and aesthetic medicine presence. Competes with BNC in Korea and selected export markets with established global distribution capabilities.
  • Galderma: Global leader in dermatology and aesthetic medicine with Restylane, Sculptra, and Dysport franchises. Sets competitive benchmarks for HA fillers and botulinum toxin; broad incumbent rather than direct peer due to scale.

Regional players

  • BioPlus (Collagen Wound Care): Korean biomaterials company producing absorbable collagen-based wound dressings and surgical implants. Direct peer in collagen wound dressing and tissue supplement categories overlapping with GentaQ and Collapleo product lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BNC KOREA social profiles

Digital presence

BNC KOREA compliance and trust

Trust signal

Compliance10 records

BNC KOREA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BNC KOREA leadership team

Management profile

Number of profiles

Profiles1 record

BNC KOREA funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BNC KOREA M&A and investment

M&A and investment

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BNC KOREA

What does BNC KOREA do?

BNC KOREA is a Korean bio-venture company that develops, manufactures, and sells biomaterial-based medical devices, specialty pharmaceuticals, and cosmeceuticals. Core products include hyaluronic acid dermal fillers (Cutegel, FLORE, Juvegel), botulinum toxin type A (BIENOX), anti-adhesion barrier gel (Hibarry), collagen-based wound dressings (GentaQ) and tissue supplements (Collapleo), and the I.st premium cosmetic brand. The company operates GMP-certified manufacturing facilities and exports to 45 countries via OEM partnerships and local distributors.

Is BNC KOREA a public or private company?

BNC KOREA is a public company. It is classified as public and is currently operating.

When was BNC KOREA founded?

BNC KOREA was founded in 2007. It employs 11 to 50 people.

Where is BNC KOREA based?

BNC KOREA is headquartered in Seoul, South Korea, in the Asia region.

How does BNC KOREA make money?

Four revenue lines are on record. Medical Device Sales are the primary driver. The others are OEM/ODM Export Manufacturing, pharmaceutical Product Sales and cosmeceutical Products (I.st Brand).

Who are BNC KOREA's main competitors?

Direct peers on record are Hugel, Medytox, Sinclair Pharma, Croma-Pharma, Teoxane and Revance Therapeutics. Broad incumbents are LG Chem (Life Sciences Division), Daewoong Pharmaceutical and Galderma. BioPlus (Collagen Wound Care) is listed as a regional player.

Does BNC KOREA have an API?

No public API is recorded for BNC KOREA.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NateInvestor Sentiment Rebounds, HLB·VUNO·BNC Korea Drive Market Turning Point[K-Bio Pulse] : 네이트 뉴스HLB Therapeutics, VUNO, and BNC Korea all hit daily price limits, with HLB rising 30% on US FDA full approval of LYRFIGTU for cholangiocarcinoma. VUNO surged 29.98% on a China distribution deal, and BNC Korea rose 29.98% on preclinical obesity data. The bio sector is realigning around companies with tangible clinical data and regulatory approvals.NaverInvestor Sentiment Rebounds, HLB·VUNO·BNC Korea Drive Market Turning Point[K-Bio Pulse]HLB, VUNO, and BNC Korea hit daily price limits on the 28th, driven by the US FDA's full approval of HLB's LYRFIGTU for cholangiocarcinoma and VUNO's China distribution deal. BNC Korea's obesity candidate showed 30% weight loss in mice. The bio sector's thaw signals a turning point, though VUNO faces assessment risks and BNC's preclinical data remains early.The future of tradingBNC Korea chair Choi Wan Gyu keeps 19.62% voting stake after share pledge loan extension disclosureBNC Korea's controlling shareholder filed a disclosure on Sept. 23, 2026, triggered by a partial extension of a share-backed loan. The chair's total holdings remained at 13,638,918 shares (19.94%), with voting rights at 13,418,918 shares (19.62%), unchanged.GlobeNewswireLeios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South KoreaLeios Therapeutics and BNC Korea announced a licensing agreement and equity investment for 10XB-101, an injectable for focal fat reduction. BNC Korea will develop and commercialize the product in nine territories, including South Korea, Taiwan, Singapore, Indonesia, Thailand, Vietnam, Russia, Belarus, and Kazakhstan. The deal follows Phase 2b results showing 64% and 70% of completers in higher dose groups achieved grade 2 or greater improvement.PR NewswireCovid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 CountriesGolden Biotechnology Corp., a Taiwanese biopharmaceutical company, announced that its COVID-19 drug candidate Antroquinonol (HOCENA) received a positive response from an independent Data Monitoring Committee (DMC) after reviewing Phase 2 clinical trial data, allowing the trial to proceed without modifications for treating mild to moderate hospitalized COVID-19 patients. The company also signed its first global licensing agreement with South Korea's BNC Korea Co., Ltd. for development and commercialization in South Korea, Russia, Ukraine, and Turkey, worth up to USD 18 million plus 25% commercial royalty upon regulatory approval. GoldenBiotech has expanded clinical trial centers to the US, Peru, and Argentina, with completion expected by Q2 2021, and will seek US Emergency Use Authorization once significant clinical results are demonstrated.